A84E45CA-971F-45D8-B7C7-E3562F2B51F3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 50.82128777923784
- age_years
- 34
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.589
- E2F_TARGETS+0.580
- MYC_TARGETS_V2+0.568
- MYC_TARGETS_V1+0.541
- DNA_REPAIR+0.437
- MITOTIC_SPINDLE+0.425
- UNFOLDED_PROTEIN_RESPONSE+0.373
- TGF_BETA_SIGNALING+0.362
- PROTEIN_SECRETION+0.361
- WNT_BETA_CATENIN_SIGNALING+0.334
Top 10 suppressed
- MYOGENESIS-0.409
- KRAS_SIGNALING_DN-0.397
- ANGIOGENESIS-0.242
- IL6_JAK_STAT3_SIGNALING-0.232
- HYPOXIA-0.224
- COAGULATION-0.221
- TNFA_SIGNALING_VIA_NFKB-0.216
- INFLAMMATORY_RESPONSE-0.193
- ESTROGEN_RESPONSE_LATE-0.191
- XENOBIOTIC_METABOLISM-0.186
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8BC036E8-0EA0-4346-A551-2A5F8975FEAB | — | — | 0.952 |
| 2 | SRR934879 | — | — | 0.947 |
| 3 | SRR934724 | — | — | 0.937 |
| 4 | SRR934928 | — | — | 0.925 |
| 5 | 9F4AEC07-5C91-4009-BA26-E4947CAA3391 | — | — | 0.924 |
| 6 | SRR934990 | — | — | 0.919 |
| 7 | CBB97C4E-43C7-4257-A85E-1F72BA71EF91 | — | — | 0.916 |
| 8 | 0D600773-1B42-4F04-BCEA-39F658DF63F1 | — | — | 0.916 |
| 9 | A1E55AC6-A41F-454A-A3B6-8F49D2AAFEF2 | — | — | 0.906 |
| 10 | C635C019-A66D-42B7-911C-4D0742CAF95A | — | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.589 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.568 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.541 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.437 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.425 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.373 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.362 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.361 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.334 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.251 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.247 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.153 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.133 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.103 | Inavolisib | — uncovered |
| PEROXISOME | 0.103 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.099 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.096 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.055 | Inavolisib | — uncovered |